BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

Susan Desmond-Hellmann joined VC firm GV as an adviser. She recently joined the board of Pfizer Inc. (NYSE:PFE) after stepping down as CEO of the Bill & Melinda Gates Foundation in December. Previously, she spent...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BC Extra | Dec 5, 2019
Company News

Dec. 4 Company Quick Takes: Allakos on the block?; plus Aurinia, Tecentriq, Gatehouse-AZ, Novartis-Amazon, Merck KGaA-Ping An and ICT

Allakos shares jump on report of potential sale Allakos Inc. (NASDAQ:ALLK) declined to comment on a Bloomberg report citing unnamed sources that the company has hired a financial adviser to explore strategic options, including a...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BC Innovations | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Rat studies suggest promoting the expression of TRESK or inhibiting its negative regulators VEGF and VEGFR2 could help treat pain associated with bone metastasis. In a rat model of bone metastasis-associated pain, TRESK...
BC Innovations | May 9, 2018
Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
BC Week In Review | Jan 19, 2018
Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
BC Innovations | Jan 4, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
Items per page:
1 - 10 of 229